These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 18383356

  • 1. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
    Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F.
    Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR, Hay J.
    Pharmacoeconomics; 2006 Apr; 24(12):1221-32. PubMed ID: 17129076
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 10. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Mar; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 12. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study.
    Gilbert TD, Smith D, Ollendorf DA.
    BMC Musculoskelet Disord; 2004 Oct 14; 5(1):36. PubMed ID: 15485582
    [Abstract] [Full Text] [Related]

  • 13. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.
    Int J Immunopathol Pharmacol; 2009 Oct 14; 22(4):1147-52. PubMed ID: 20074482
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effectiveness of TNF antagonists in routine clinical practice and costs].
    Prokes M.
    Vnitr Lek; 2009 Jan 14; 55(1):45-53. PubMed ID: 19227955
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.